|
|||||
|
|
Population pharmacokinetics of erlotinib in Japanese patients with advanced non‐small cell lung cancer |
|
| Authors: | Y. Emoto‐Yamamoto MSc S. Iida PhD T. Kawanishi MSc M. Fukuoka PhD |
| Affiliation: | 1. Clinical Research Planning Department, Chugai Pharmaceutical Co. Ltd., Tokyo, Japan;2. Cancer Center, Izumi Municipal Hospital, Osaka, Japan |
| Abstract: | |
| Keywords: | advanced non‐small cell lung cancer erlotinib interstitial lung disease nonlinear mixed‐effects modelling population pharmacokinetics |